Kulcskérdések a hepatitis C kezelésében

Translated title of the contribution: Crucial points in the therapy of hepatitis c

Makara Mihály, B. Hunyady

Research output: Contribution to journalArticle

Abstract

The first generation of direct acting antivirals represented a milestone in the therapy of hepatitis C but other breakthroughs are on the way with imminent authorization of new antiviral drugs and interferon-free= combinations. The prices of these new agents necessitate the rational use of limited financial capacities: relatively cheaper interferon-based treatments could be used first for those who can be cured with these combinations, while the most expensive treatments are to be reserved for those with no other options. In the future, interferonfree regimens will likely be used first in those patients who did not respond to firstgeneration interferon-based regimens and in whom interferon therapy is contraindicated. To avoid complications of the disease, currently it is reasonable to treat all eligible patients with advanced fibrosis, particularly those with compensated cirrhosis, with interferon-based treatments. In some instances other medical or social conditions warrant prompt treatment. The triage of treatments is based on the PriorityIndex in Hungary. Current triple therapies with protease inhibitors are complicated by drug and food interactions as well as by frequent (sometimes severe) side effects. General practitioners and other specialists need to be involved in managing these issues. It is of utmost importance to refer patients to hepatology care before decompensation or development of hepatocellular carcinoma. The key of timely and accurate diagnosis is organized anti-HCV screening in populations at risk and in the age group with the highest prevalence.

Original languageHungarian
Pages (from-to)94-98
Number of pages5
JournalLege Artis Medicinae
Volume24
Issue number3
Publication statusPublished - 2014

Fingerprint

Hepatitis
Interferons
Therapeutics
Antiviral Agents
Fibrosis
Food-Drug Interactions
Hungary
Triage
Social Conditions
Gastroenterology
Hepatitis C
Protease Inhibitors
General Practitioners
Hepatocellular Carcinoma
Age Groups

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Kulcskérdések a hepatitis C kezelésében. / Mihály, Makara; Hunyady, B.

In: Lege Artis Medicinae, Vol. 24, No. 3, 2014, p. 94-98.

Research output: Contribution to journalArticle

Mihály, Makara ; Hunyady, B. / Kulcskérdések a hepatitis C kezelésében. In: Lege Artis Medicinae. 2014 ; Vol. 24, No. 3. pp. 94-98.
@article{a340cc81548844f487a1a783002c6ff8,
title = "Kulcsk{\'e}rd{\'e}sek a hepatitis C kezel{\'e}s{\'e}ben",
abstract = "The first generation of direct acting antivirals represented a milestone in the therapy of hepatitis C but other breakthroughs are on the way with imminent authorization of new antiviral drugs and interferon-free= combinations. The prices of these new agents necessitate the rational use of limited financial capacities: relatively cheaper interferon-based treatments could be used first for those who can be cured with these combinations, while the most expensive treatments are to be reserved for those with no other options. In the future, interferonfree regimens will likely be used first in those patients who did not respond to firstgeneration interferon-based regimens and in whom interferon therapy is contraindicated. To avoid complications of the disease, currently it is reasonable to treat all eligible patients with advanced fibrosis, particularly those with compensated cirrhosis, with interferon-based treatments. In some instances other medical or social conditions warrant prompt treatment. The triage of treatments is based on the PriorityIndex in Hungary. Current triple therapies with protease inhibitors are complicated by drug and food interactions as well as by frequent (sometimes severe) side effects. General practitioners and other specialists need to be involved in managing these issues. It is of utmost importance to refer patients to hepatology care before decompensation or development of hepatocellular carcinoma. The key of timely and accurate diagnosis is organized anti-HCV screening in populations at risk and in the age group with the highest prevalence.",
keywords = "Direct effect anti-HCV antiviral agent, Hepatitis C, Pegilated interferon, Protease inhibitor boceprevir, Sofosbuvir, Telaprevir",
author = "Makara Mih{\'a}ly and B. Hunyady",
year = "2014",
language = "Hungarian",
volume = "24",
pages = "94--98",
journal = "Lege Artis Medicinae",
issn = "0866-4811",
publisher = "Literatura Medica Publishing House",
number = "3",

}

TY - JOUR

T1 - Kulcskérdések a hepatitis C kezelésében

AU - Mihály, Makara

AU - Hunyady, B.

PY - 2014

Y1 - 2014

N2 - The first generation of direct acting antivirals represented a milestone in the therapy of hepatitis C but other breakthroughs are on the way with imminent authorization of new antiviral drugs and interferon-free= combinations. The prices of these new agents necessitate the rational use of limited financial capacities: relatively cheaper interferon-based treatments could be used first for those who can be cured with these combinations, while the most expensive treatments are to be reserved for those with no other options. In the future, interferonfree regimens will likely be used first in those patients who did not respond to firstgeneration interferon-based regimens and in whom interferon therapy is contraindicated. To avoid complications of the disease, currently it is reasonable to treat all eligible patients with advanced fibrosis, particularly those with compensated cirrhosis, with interferon-based treatments. In some instances other medical or social conditions warrant prompt treatment. The triage of treatments is based on the PriorityIndex in Hungary. Current triple therapies with protease inhibitors are complicated by drug and food interactions as well as by frequent (sometimes severe) side effects. General practitioners and other specialists need to be involved in managing these issues. It is of utmost importance to refer patients to hepatology care before decompensation or development of hepatocellular carcinoma. The key of timely and accurate diagnosis is organized anti-HCV screening in populations at risk and in the age group with the highest prevalence.

AB - The first generation of direct acting antivirals represented a milestone in the therapy of hepatitis C but other breakthroughs are on the way with imminent authorization of new antiviral drugs and interferon-free= combinations. The prices of these new agents necessitate the rational use of limited financial capacities: relatively cheaper interferon-based treatments could be used first for those who can be cured with these combinations, while the most expensive treatments are to be reserved for those with no other options. In the future, interferonfree regimens will likely be used first in those patients who did not respond to firstgeneration interferon-based regimens and in whom interferon therapy is contraindicated. To avoid complications of the disease, currently it is reasonable to treat all eligible patients with advanced fibrosis, particularly those with compensated cirrhosis, with interferon-based treatments. In some instances other medical or social conditions warrant prompt treatment. The triage of treatments is based on the PriorityIndex in Hungary. Current triple therapies with protease inhibitors are complicated by drug and food interactions as well as by frequent (sometimes severe) side effects. General practitioners and other specialists need to be involved in managing these issues. It is of utmost importance to refer patients to hepatology care before decompensation or development of hepatocellular carcinoma. The key of timely and accurate diagnosis is organized anti-HCV screening in populations at risk and in the age group with the highest prevalence.

KW - Direct effect anti-HCV antiviral agent

KW - Hepatitis C

KW - Pegilated interferon

KW - Protease inhibitor boceprevir

KW - Sofosbuvir

KW - Telaprevir

UR - http://www.scopus.com/inward/record.url?scp=84899740708&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84899740708&partnerID=8YFLogxK

M3 - Article

VL - 24

SP - 94

EP - 98

JO - Lege Artis Medicinae

JF - Lege Artis Medicinae

SN - 0866-4811

IS - 3

ER -